tiprankstipranks
Trending News
More News >
Atara Biotherapeutics Inc (ATRA)
:ATRA
Advertisement

Atara Biotherapeutics (ATRA) Stock Statistics & Valuation Metrics

Compare
1,150 Followers

Total Valuation

Atara Biotherapeutics has a market cap or net worth of $78.49M. The enterprise value is $130.96M.
Market Cap$78.49M
Enterprise Value$130.96M

Share Statistics

Atara Biotherapeutics has 6,795,628 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,795,628
Owned by Insiders23.61%
Owned by Institutions19.14%

Financial Efficiency

Atara Biotherapeutics’s return on equity (ROE) is 0.88 and return on invested capital (ROIC) is 721.74%.
Return on Equity (ROE)0.88
Return on Assets (ROA)-0.78
Return on Invested Capital (ROIC)721.74%
Return on Capital Employed (ROCE)3.28
Revenue Per Employee842.75K
Profits Per Employee-558.19K
Employee Count153
Asset Turnover1.18
Inventory Turnover1.97

Valuation Ratios

The current PE Ratio of Atara Biotherapeutics is ―. Atara Biotherapeutics’s PEG ratio is ―.
PE Ratio
PS Ratio0.00
PB Ratio0.00
Price to Fair Value-1.02
Price to FCF0.00
Price to Operating Cash Flow-1.49
PEG Ratio

Income Statement

In the last 12 months, Atara Biotherapeutics had revenue of 128.94M and earned -85.40M in profits. Earnings per share was -11.41.
Revenue128.94M
Gross Profit107.93M
Operating Income-83.44M
Pretax Income-85.42M
Net Income-85.40M
EBITDA-75.75M
Earnings Per Share (EPS)-11.41

Cash Flow

In the last 12 months, operating cash flow was -67.24M and capital expenditures -119.00K, giving a free cash flow of -67.36M billion.
Operating Cash Flow-67.24M
Free Cash Flow-67.36M
Free Cash Flow per Share-9.91

Dividends & Yields

Atara Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.06
52-Week Price Change46.28%
50-Day Moving Average9.30
200-Day Moving Average9.12
Relative Strength Index (RSI)58.13
Average Volume (3m)52.09K

Important Dates

Atara Biotherapeutics upcoming earnings date is Aug 11, 2025, TBA (Confirmed).
Last Earnings DateMay 15, 2025
Next Earnings DateAug 11, 2025
Ex-Dividend Date

Financial Position

Atara Biotherapeutics as a current ratio of 0.48, with Debt / Equity ratio of -48.50%
Current Ratio0.48
Quick Ratio0.40
Debt to Market Cap0.00
Net Debt to EBITDA-0.25
Interest Coverage Ratio-18.08

Taxes

In the past 12 months, Atara Biotherapeutics has paid -12.00K in taxes.
Income Tax-12.00K
Effective Tax Rate<0.01

Enterprise Valuation

Atara Biotherapeutics EV to EBITDA ratio is -1.56, with an EV/FCF ratio of -1.72.
EV to Sales0.92
EV to EBITDA-1.56
EV to Free Cash Flow-1.72
EV to Operating Cash Flow-1.72

Balance Sheet

Atara Biotherapeutics has $13.84M in cash and marketable securities with $26.71M in debt, giving a net cash position of $12.87M billion.
Cash & Marketable Securities$13.84M
Total Debt$26.71M
Net Cash$12.87M
Net Cash Per Share$1.89
Tangible Book Value Per Share-$12.99

Margins

Gross margin is 80.24%, with operating margin of -64.71%, and net profit margin of -66.23%.
Gross Margin80.24%
Operating Margin-64.71%
Pretax Margin-66.24%
Net Profit Margin-66.23%
EBITDA Margin-58.75%
EBIT Margin-62.66%

Analyst Forecast

The average price target for Atara Biotherapeutics is $17.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$17.00
Price Target Upside51.52% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast475.53%
EPS Growth Forecast89.94%

Scores

Smart Score7
AI Score51
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis